Celgene is set to apply machine learning to market access, commercialisation and drug discovery through a partnership with GNS Healthcare.
GNS applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients.
The service and license arrangement with Celgene covers its REFS (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform.
The deal, which involves Celgene’s second equity investment in the firm, will also see several GNS causal modeling experts brought in-house at the biopharma company’s sites to operate the platform.
Iya Khalil, chief commercial officer and co-founder of GNS, said: “Companies that embrace data-driven frameworks and culture such as Celgene are gaining a competitive advantage to rapidly generate insights that are simply not possible with any other analytics methodology.”
In addition to Celgene, GNS has previously worked with the likes of J&J, Novartis, Covance and the US National Institutes of Health.
